Latest Information Update: 11 Jul 2016
At a glance
- Originator Amgen
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 01 Jun 2016 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA, Australia (IV) (NCT02675452)
- 12 Feb 2016 Amgen plans a first-in-human phase I trial for Multiple myeloma (Second-line therapy or greater) in USA, Germany and Australia (IV) (NCT02675452)
- 22 Dec 2015 Preclinical trials in Multiple myeloma in USA (IV) before December 2015